

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

LIGNELL et al.

U.S. National Phase of PCT/SE00/01923

Entry papers filed herewith March 28, 2002

For: Use of Xanthophylls, Astaxanthin e.g., for Treatment of Autoimmune Diseases, Chronic Viral and Intracellular Bacterial Infections

Attention: PCT OFFICE

**PRELIMINARY AMENDMENT  
AND INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The present application is the U.S. national phase of international application number PCT/SE00/01923.

Please amend the above-identified application as follows:

**IN THE SPECIFICATION:**

✓ Please add the attached ABSTRACT OF THE DISCLOSURE to the application.

**IN THE CLAIMS:**

Please cancel claims 1-8 without prejudice or disclaimer.

Please replace claim 14 with the following amended claim 14.

AA 14(Amended). The method according to claim 12, wherein the astaxanthin is derived from a natural source.